propranolol has been researched along with Cancer Syndromes, Hereditary in 43 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication." | 7.78 | Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding? ( Buffon, RB; Cavalli, R; Colli, AM; de Souza, M; Gelmetti, C, 2012) |
| "Propranolol-induced involution is a unique biological feature of some pediatric vascular tumors, for instance infantile hemangioma (IH), cerebral cavernoma or chorioangioma." | 3.83 | The embryo-placental CD15-positive "vasculogenic zones" as a source of propranolol-sensitive pediatric vascular tumors. ( Anspach, L; Roth, W; Seidmann, L, 2016) |
| "A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication." | 3.78 | Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding? ( Buffon, RB; Cavalli, R; Colli, AM; de Souza, M; Gelmetti, C, 2012) |
| " However, other less lipophilic β-blockers, such as nadolol, may be preferable in individuals who experience propranolol unresponsiveness or adverse events." | 3.11 | Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial. ( Drolet, B; Kanigsberg, N; Lara-Corrales, I; Liy-Wong, C; Ma, J; Pope, E; Sibbald, C, 2022) |
| "Propranolol has revolutionized the treatment of infantile hemangiomas, and other beta-blockers provide promising alternatives." | 2.52 | Beta-blockers for childhood vascular tumors. ( Bayart, CB; Brandling-Bennett, HA, 2015) |
| "Our observations show that gradually increasing the dosage of propranolol up to 3 mg/kg and gradually weaning the dosage is safe and effective in treatment of problematic IH." | 2.50 | Treatment of problematic infantile hemangiomas with propranolol: a series of 40 cases and review of the literature. ( Dębek, W; Dzienis-Koronkiewicz, E; Hermanowicz, A; Matuszczak, E; Oksiuta, M; Tylicka, M, 2014) |
| "Congenital or atypical nevi of the child benefit from genetic progress or improvement of clinical knowledge." | 2.49 | [What’s new in pediatric dermatology?]. ( Lacour, JP, 2013) |
| "Propranolol has been the first-line treatment for alarming hemangiomas." | 1.48 | Intralesional Bleomycin Injection for Propranolol-Resistant Hemangiomas. ( Chang, L; Chen, H; Jin, Y; Lin, X; Ma, G; Yang, X, 2018) |
| " Atenolol and prednisolone are effective and safe alternatives to propranolol in the treatment of refractory IHs." | 1.48 | Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. ( Chen, S; Ji, Y; Lu, G; Qiu, L; Wang, Q; Xiang, B; Xu, Z; Yang, K; Zhong, L, 2018) |
| "Propranolol treatment (2 mg/kg/day in three doses) for infantile haemangioma is well tolerated and safe and may be administered and monitored in an ambulatory setting." | 1.48 | Safety profile during initiation of propranolol for treatment of infantile haemangiomas in an ambulatory day-care hospitalization setting. ( Atar Snir, V; Ben-Amitai, D; Fogel, I; Friedland, R; Lapidoth, M; Ollech, A; Valdman-Greenshpon, Y; Zvulunov, A, 2018) |
| "Propranolol is an effective drug in treating IH." | 1.46 | Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol. ( Alvarenga, JG; Bouer, M; de Oliveira Labinas, GH; de Oliveira, ZN; Rivitti-Machado, MC; Rotter, A; Samorano, LP; Santos, PC; Silvestre, DA, 2017) |
| "Propranolol 4% gel is a safe and efficient topical therapy for IH." | 1.46 | Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas. ( Goldberg, I; Harel, A; Ilan, EB; Kutz, A; Mashiah, J; Rabia, SH; Sprecher, E, 2017) |
| "Propranolol is a well-tolerated, efficacious, and safe drug for treatment of IH." | 1.43 | Treatment with propranolol for infantile hemangiomas: single-center experience. ( Bör, Ö; Özdemir, ZC; Turhan, AB, 2016) |
| "Propranolol was initiated at 0." | 1.42 | Scoring the therapeutic effects of oral propranolol for infantile hemangioma: A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS). ( de Laat, PC; Janmohamed, SR; Madern, GC; Oranje, AP; van Oosterhout, M; van Rosmalen, J, 2015) |
| "Propranolol (a β-blocker) is a safe treatment for problematic IH." | 1.40 | Propranolol in infantile haemangioma: simplifying pretreatment monitoring. ( de Buys Roessingh, A; El Ezzi, O; Hohlfeld, J, 2014) |
| "Oral propranolol is now the treatment of choice in many situations." | 1.39 | Ulcerated nasal infantile haemangioma treated by oral propranolol. ( Al Dosari, S; Riad, H, 2013) |
| "Propranolol was stopped in 1 case for hypotension and in 1 case for allergy." | 1.39 | Treatment of infantile capillary hemangioma of the eyelid with systemic propranolol. ( Di Mezza, A; Forte, R; Magli, A; Vassallo, P, 2013) |
| " A treatment dosage of 2 mg/kg per day was started at mean age 5." | 1.37 | Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol. ( Ben-Amitay, D; Friling, R; Goldenberg-Cohen, N; Reich, U; Ron, Y; Siegel, R; Snir, M; Zvulunov, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 41 (95.35) | 24.3611 |
| 2020's | 2 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| Pope, E | 1 |
| Lara-Corrales, I | 1 |
| Sibbald, C | 1 |
| Liy-Wong, C | 1 |
| Kanigsberg, N | 1 |
| Drolet, B | 1 |
| Ma, J | 1 |
| Moisan, F | 1 |
| Oucherif, S | 1 |
| Kaulanjan-Checkmodine, P | 1 |
| Prey, S | 1 |
| Rousseau, B | 1 |
| Bonneu, M | 1 |
| Claverol, S | 1 |
| Gontier, E | 1 |
| Lacomme, S | 1 |
| Dousset, L | 1 |
| Couffinhal, T | 1 |
| Toutain, J | 1 |
| Loot, M | 1 |
| Cario-André, M | 1 |
| Jullié, ML | 1 |
| Léauté-Labrèze, C | 1 |
| Taieb, A | 1 |
| Rezvani, HR | 1 |
| Marey, HM | 1 |
| Elmazar, HF | 1 |
| Mandour, SS | 1 |
| Khairy, HA | 1 |
| Koka, K | 1 |
| Mukherjee, B | 1 |
| Agarkar, S | 1 |
| Chang, L | 1 |
| Chen, H | 1 |
| Yang, X | 1 |
| Jin, Y | 1 |
| Ma, G | 1 |
| Lin, X | 1 |
| Onnis, G | 1 |
| Dreyfus, I | 1 |
| Mazereeuw-Hautier, J | 1 |
| Seamens, A | 1 |
| Nieman, E | 1 |
| Losavio, K | 1 |
| Bradley, B | 1 |
| Nelson, K | 1 |
| Chen, KH | 1 |
| Chen, S | 2 |
| Arbiser, J | 1 |
| Lawley, LP | 1 |
| Ji, Y | 1 |
| Wang, Q | 1 |
| Xiang, B | 1 |
| Xu, Z | 1 |
| Zhong, L | 1 |
| Yang, K | 1 |
| Lu, G | 1 |
| Qiu, L | 1 |
| Fogel, I | 1 |
| Ollech, A | 1 |
| Zvulunov, A | 2 |
| Valdman-Greenshpon, Y | 1 |
| Atar Snir, V | 1 |
| Friedland, R | 1 |
| Lapidoth, M | 1 |
| Ben-Amitai, D | 1 |
| Xu, MN | 1 |
| Zhang, M | 1 |
| Xu, Y | 1 |
| Wang, M | 1 |
| Yuan, SM | 1 |
| Ganti, AK | 1 |
| Ray, J | 1 |
| Mooney, KL | 1 |
| Zambrano, E | 1 |
| Hillard, PJA | 1 |
| Fok, W | 1 |
| Babic, V | 1 |
| Schoeffler, A | 1 |
| Moawad, S | 1 |
| Mainard, L | 1 |
| Schmutz, JL | 1 |
| Bursztejn, AC | 1 |
| Krick, J | 1 |
| Riehle, K | 1 |
| Chapman, T | 1 |
| Chabra, S | 1 |
| Ho, W | 1 |
| Hoo, C | 1 |
| Black, C | 1 |
| Lee, KC | 1 |
| Bercovitch, L | 1 |
| Al Dosari, S | 1 |
| Riad, H | 1 |
| Herschthal, J | 1 |
| Wulkan, A | 1 |
| George, M | 1 |
| Waibel, J | 1 |
| May, JE | 1 |
| Liew, SH | 1 |
| Lacour, JP | 1 |
| El Ezzi, O | 1 |
| Hohlfeld, J | 1 |
| de Buys Roessingh, A | 1 |
| Bellaud, G | 1 |
| Puzenat, E | 1 |
| Billon-Grand, NC | 1 |
| Humbert, P | 1 |
| Aubin, F | 1 |
| Janmohamed, SR | 2 |
| Madern, GC | 2 |
| de Laat, PC | 2 |
| Oranje, AP | 2 |
| Oksiuta, M | 1 |
| Matuszczak, E | 1 |
| Dębek, W | 1 |
| Dzienis-Koronkiewicz, E | 1 |
| Hermanowicz, A | 1 |
| Tylicka, M | 1 |
| Natawidjaja, R | 1 |
| Ewen Wang, N | 1 |
| Jacks, SK | 1 |
| Kertesz, NJ | 1 |
| Witman, PM | 1 |
| Fernandez Faith, E | 1 |
| Bayart, CB | 1 |
| Brandling-Bennett, HA | 1 |
| van Oosterhout, M | 1 |
| van Rosmalen, J | 1 |
| Moyakine, AV | 2 |
| Hermans, DJ | 1 |
| Fuijkschot, J | 1 |
| van der Vleuten, CJ | 2 |
| Seidmann, L | 1 |
| Anspach, L | 1 |
| Roth, W | 1 |
| Kerstjens, JM | 1 |
| Spillekom-van Koulil, S | 1 |
| Turhan, AB | 1 |
| Bör, Ö | 1 |
| Özdemir, ZC | 1 |
| Rizvi, SA | 1 |
| Mehmood, F | 1 |
| Agrawal, A | 1 |
| Rotter, A | 1 |
| Samorano, LP | 1 |
| de Oliveira Labinas, GH | 1 |
| Alvarenga, JG | 1 |
| Rivitti-Machado, MC | 1 |
| Bouer, M | 1 |
| Santos, PC | 1 |
| Silvestre, DA | 1 |
| de Oliveira, ZN | 1 |
| Mashiah, J | 1 |
| Kutz, A | 1 |
| Rabia, SH | 1 |
| Ilan, EB | 1 |
| Goldberg, I | 1 |
| Sprecher, E | 1 |
| Harel, A | 1 |
| Smithson, SL | 1 |
| Rademaker, M | 1 |
| Adams, S | 1 |
| Bade, S | 1 |
| Bekhor, P | 1 |
| Davidson, S | 1 |
| Dore, A | 1 |
| Drummond, C | 1 |
| Fischer, G | 1 |
| Gin, A | 1 |
| Grills, C | 1 |
| Halbert, A | 1 |
| Lokmic, Z | 1 |
| McCahon, E | 1 |
| Morgan, VA | 1 |
| Murrell, DF | 1 |
| Orchard, D | 1 |
| Penington, A | 1 |
| Purvis, D | 1 |
| Relic, J | 1 |
| Robertson, S | 1 |
| Robinson, AJ | 1 |
| Scardamaglia, L | 1 |
| Su, J | 1 |
| Tan, S | 1 |
| Wargon, O | 1 |
| Warren, L | 1 |
| Wong, LC | 1 |
| Zappala, T | 1 |
| Phillips, R | 1 |
| Mai, C | 1 |
| Vega-Pérez, A | 1 |
| Koch, M | 1 |
| Bertelmann, E | 1 |
| Sciveres, M | 1 |
| Marrone, G | 1 |
| Pipitone, S | 1 |
| Riva, S | 1 |
| Spada, M | 1 |
| Gridelli, B | 1 |
| Maggiore, G | 1 |
| Koay, AC | 1 |
| Choo, MM | 1 |
| Nathan, AM | 1 |
| Omar, A | 1 |
| Lim, CT | 1 |
| Snir, M | 1 |
| Reich, U | 1 |
| Siegel, R | 1 |
| Friling, R | 1 |
| Goldenberg-Cohen, N | 1 |
| Ron, Y | 1 |
| Ben-Amitay, D | 1 |
| Williams, K | 1 |
| Woolf, R | 1 |
| Morrison, D | 1 |
| Cavalli, R | 1 |
| Buffon, RB | 1 |
| de Souza, M | 1 |
| Colli, AM | 1 |
| Gelmetti, C | 1 |
| Hirahara, S | 1 |
| Matsuda, K | 1 |
| Toyama, K | 1 |
| Nagano, Y | 1 |
| Nagai, N | 1 |
| Tono, T | 1 |
| Vassallo, P | 1 |
| Forte, R | 1 |
| Di Mezza, A | 1 |
| Magli, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nadolol Versus Propranolol in Children With Infantile Hemangiomas: a Randomized, Controlled, Double-blinded Trial[NCT02505971] | Phase 3 | 74 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for propranolol and Cancer Syndromes, Hereditary
| Article | Year |
|---|---|
[Rare presentations of infantile hemangiomas: 4 cases].
Topics: Biopsy; Buttocks; Delayed Diagnosis; Erythema; Facial Neoplasms; Female; Foot Diseases; Hemangioma, | 2018 |
Update on infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Male; N | 2013 |
[What’s new in pediatric dermatology?].
Topics: Adolescent; Child; Dermatitis, Atopic; Dermatology; Hemangioma, Capillary; Humans; Melanoma; Neoplas | 2013 |
Educational paper: Pathogenesis of infantile haemangioma, an update 2014 (part I).
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Hypoxia-Inducible Factor 1, alpha Subuni | 2015 |
Treatment of problematic infantile hemangiomas with propranolol: a series of 40 cases and review of the literature.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; In | 2014 |
Beta-blockers for childhood vascular tumors.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Atenolol; Child, Prescho | 2015 |
2 trials available for propranolol and Cancer Syndromes, Hereditary
| Article | Year |
|---|---|
Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Double-Blind Method; Equivalence Trials as Topic; | 2022 |
Combined Oral and Topical Beta Blockers for the Treatment of Early Proliferative Superficial Periocular Infantile Capillary Hemangioma.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Drug Therapy, Combinatio | 2018 |
35 other studies available for propranolol and Cancer Syndromes, Hereditary
| Article | Year |
|---|---|
Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade.
Topics: Adrenergic beta-Antagonists; Animals; Aquaporin 1; Cell Line, Tumor; Cell Movement; Hemangioma, Capi | 2021 |
Effect of oral propranolol on periocular Capillary Hemangiomas of Infancy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Ma | 2018 |
Intralesional Bleomycin Injection for Propranolol-Resistant Hemangiomas.
Topics: Antibiotics, Antineoplastic; Bleomycin; Drug Resistance, Neoplasm; Hemangioma, Capillary; Humans; In | 2018 |
Factors associated with delayed referral for infantile hemangioma necessitating propranolol.
Topics: Age of Onset; Clinical Competence; Female; Health Knowledge, Attitudes, Practice; Hemangioma, Capill | 2018 |
Salivary levels of angiopoietin-2 in infants with infantile haemangiomas treated with and without systemic propranolol.
Topics: Angiopoietin-2; Female; Hemangioma, Capillary; Humans; Infant; Male; Neoplastic Syndromes, Hereditar | 2018 |
Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management.
Topics: Adrenergic beta-Antagonists; Drug-Related Side Effects and Adverse Reactions; Female; Hemangioma, Ca | 2018 |
Safety profile during initiation of propranolol for treatment of infantile haemangiomas in an ambulatory day-care hospitalization setting.
Topics: Ambulatory Care; Analysis of Variance; Child, Preschool; Cohort Studies; Dose-Response Relationship, | 2018 |
Individualized Treatment for Infantile Hemangioma.
Topics: Administration, Cutaneous; Administration, Oral; Betamethasone; Carteolol; Female; Glucocorticoids; | 2018 |
Unusual Cause of Pediatric Vaginal Bleeding: Infantile Capillary Hemangioma of the Cervix.
Topics: Adrenergic beta-Antagonists; Cervix Uteri; Child; Diagnosis, Differential; Endoscopy; Female; Hemang | 2019 |
Recurrent bloody stools associated with visceral infantile haemangioma in a preterm twin girl.
Topics: Adrenergic beta-Antagonists; Diagnosis, Differential; Female; Gastrointestinal Hemorrhage; Hemangiom | 2018 |
Treatment of Infantile Haemangioma - Perspective of a Regional Surgical Centre.
Topics: Child; Child, Preschool; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Heman | 2019 |
Ulcerated nasal infantile haemangioma treated by oral propranolol.
Topics: Administration, Oral; Drug Administration Schedule; Female; Hemangioma, Capillary; Humans; Infant; N | 2013 |
Additive effect of propranolol and pulsed dye laser for infantile hemangioma.
Topics: Combined Modality Therapy; Female; Hemangioma, Capillary; Humans; Infant; Infant, Premature; Infant, | 2013 |
A new treatment pathway for propranolol use in infantile haemangiomas.
Topics: Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Neoplastic Syndromes, Hereditary; Parents; P | 2014 |
Propranolol in infantile haemangioma: simplifying pretreatment monitoring.
Topics: Blood Glucose; Blood Pressure; Drug Monitoring; Echocardiography; Electrocardiography; Facial Neopla | 2014 |
PHACE syndrome, a series of six patients: clinical and morphological manifestations, propranolol efficacy, and safety.
Topics: Aortic Coarctation; Child; Child, Preschool; Eye Abnormalities; Facial Neoplasms; Female; Hemangioma | 2015 |
Nonsurgical treatment of two cases of infantile facial growths in a resource-poor setting.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Indonesia; | 2015 |
Experience with Holter monitoring during propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Age Factors; Ambulatory Care; Cardiovascular Diseases; Child, Preschool | 2015 |
Scoring the therapeutic effects of oral propranolol for infantile hemangioma: A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS).
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Cohort Studies; Dose-Response R | 2015 |
Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development.
Topics: Child, Preschool; Cohort Studies; Female; Hemangioma, Capillary; Humans; Infant; Male; Neoplastic Sy | 2015 |
The embryo-placental CD15-positive "vasculogenic zones" as a source of propranolol-sensitive pediatric vascular tumors.
Topics: Age of Onset; Cell Lineage; Child; Drug Resistance, Neoplasm; Embryo, Mammalian; Endothelial Cells; | 2016 |
Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years.
Topics: Body Height; Body Weight; Case-Control Studies; Child Development; Child, Preschool; Female; Hemangi | 2016 |
Treatment with propranolol for infantile hemangiomas: single-center experience.
Topics: Child; Child, Preschool; Female; Hemangioma, Capillary; Humans; Infant; Male; Neoplastic Syndromes, | 2016 |
Bilateral congenital infantile hemangioma of upper eyelids.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Eyelid Neoplasms; Eyelids; Female; Hemangioma, Ca | 2016 |
Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma, Capillary; Humans; Infant; Male; | 2017 |
Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Age Factors; Child, Preschool; Female; Gels; | 2017 |
Consensus statement for the treatment of infantile haemangiomas with propranolol.
Topics: Consensus; Drug Monitoring; Hemangioma, Capillary; Humans; Neoplastic Syndromes, Hereditary; Patient | 2017 |
[Successful treatment of orbital capillary hemangioma with propranolol].
Topics: Adrenergic beta-Antagonists; Biopsy; Exophthalmos; Female; Hemangioma, Capillary; Humans; Infant; Ma | 2011 |
Successful first-line treatment with propranolol of multifocal infantile hepatic hemangioma with high-flow cardiac overload.
Topics: Dose-Response Relationship, Drug; Female; Hemangioma, Capillary; Humans; Infant; Liver; Liver Transp | 2011 |
Combined low-dose oral propranolol and oral prednisolone as first-line treatment in periocular infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Therapy, Combination; Eyelid Diseases; Femal | 2011 |
Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol.
Topics: Adrenergic beta-Antagonists; Eyelid Neoplasms; Female; Hemangioma, Capillary; Humans; Infant; Male; | 2011 |
Periocular lesion in an infant.
Topics: Adrenergic beta-Antagonists; Eyelid Neoplasms; Female; Hemangioma, Capillary; Humans; Infant; Laser | 2011 |
Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding?
Topics: Antineoplastic Agents; Female; Hemangioma, Capillary; Humans; Hyperkalemia; Hyperphosphatemia; Infan | 2012 |
[A case of propranolol therapy for infantile capillary hemangiomas of the parotis].
Topics: Adrenergic beta-Antagonists; Female; Head and Neck Neoplasms; Hemangioma, Capillary; Humans; Infant; | 2012 |
Treatment of infantile capillary hemangioma of the eyelid with systemic propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Eyelid Neoplasms; Female | 2013 |